keyword
MENU ▼
Read by QxMD icon Read
search

Pemetrexed

keyword
https://www.readbyqxmd.com/read/29326243/concentrative-transport-of-antifolates-mediated-by-the-proton-coupled-folate-transporter-pcft-slc46a1-augmentation-by-a-hepes-buffer
#1
Rongbao Zhao, Mitra Najmi, Srinivas Aluri, David C Spray, I David Goldman
The proton-coupled folate transporter (PCFT) is ubiquitously expressed in solid tumors where it delivers antifolates, particularly pemetrexed, into cancer cells. Studies on PCFT-mediated transport, to date, have focused exclusively on the influx of folates and antifolates. This paper addresses the impact of PCFT on concentrative transport, critical to the formation of the active polyglutamate congeners, and at pH levels relevant to the tumor microenvironment. A HeLa-derived cell line was employed in which folate-specific transport was mediated exclusively by PCFT...
January 11, 2018: Molecular Pharmacology
https://www.readbyqxmd.com/read/29318404/does-alk-rearrangement-predict-favorable-response-to-the-therapy-of-bevacizumab-plus-pemetrexed-in-advanced-non-small-cell-lung-cancer-case-report-and-literature-review
#2
Zhichao Liu, Youting Bao, Butuo Li, Xindong Sun, Linlin Wang
BACKGROUND: Advanced ALK-rearranged non-small cell lung cancer (NSCLC) patients will develop acquired resistance after anaplastic lymphoma kinase (ALK) inhibitors therapies. Vascular endothelial growth factor-A (VEGF-A) production and tumor vessel formation were found to be more significantly enriched in ALK-rearrangement NSCLC than that in epidermal growth factor receptor or Kirsten rat sarcoma viral oncogene mutated NSCLC. However, the correlation between ALK rearrangement and the efficacy of bevacizumab (a recombinant humanized IgG1 monoclonal antibody targeting VEGF-A) was still elusive...
January 9, 2018: Clinical and Translational Medicine
https://www.readbyqxmd.com/read/29316288/carboplatin-plus-pemetrexed-for-the-elderly-incurable-chemo-naive-nonsquamous-non-small-cell-lung-cancer-meta-analysis
#3
Masaru Ito, Nobuyuki Horita, Akimichi Nagashima, Takeshi Kaneko
AIM: In some developed countries, a proportion of nonsquamous non-small cell lung cancer (NSq NSCLC) patients are aged over 70 years when they are diagnosed. However, evidence of lung cancer chemotherapy usually comes from randomized controlled trials that only recruit younger patients with good performance status. In daily practice, less-toxic carboplatin + pemetrexed regimen is often used for elderly patients, although this regimen is not sufficiently supported by rigid evidence for elderly cases...
January 8, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29310415/cisplatin-induced-sudden-cardiac-death-with-hemodynamic-collapse-a-severe-adverse-drug-reaction-case-report
#4
Silvijus Abramavicius, Marius Zemaitis, Vidas Pilvinis, Edmundas Kadusevicius
RATIONALE: Cisplatin is responsible for a significant percentage of adverse drug reactions (ADRs) in oncology setting. A great proportion of cisplatin-induced severe adverse events are difficult to foresee, and giving premedication does not always prevent the occurrence of such events. PATIENT CONCERNS: A 53-year-old woman with progressive T4 N0 M0 stage IV pleural mesothelioma experienced cardiac arrest with hemodynamic collapse after cisplatin and pemetrexed chemotherapy administration...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29308196/mandatory-dexamethasone-strictly-monitored-by-pharmacists-reduces-the-severity-of-pemetrexed-induced-skin-rash
#5
Naoko Usui, Yoko Kondo, Noriko Ryota, Hidekazu Suzuki, Norio Okamoto, Masumi Sando, Eriko Tani, Masanari Hamaguchi, Ayako Tanaka, Motohiro Tamiya, Takayuki Shiroyama, Naoko Morishita, Emiko Tanaka, Tomonori Hirashima
Objective: The present study aimed to retrospectively examine the effectiveness of mandatory dexamethasone (m-DEX) strictly monitored by pharmacists collaborating with medical physicians and nurses for reducing pemetrexed (PEM)-induced skin rash in patients with non-squamous non-small-cell lung cancer (ns-NSCLC). Methods: We compared the rash grades during the first cycle of PEM-containing regimens between patients who received m-DEX after February 2012 and those who received dexamethasone (DEX) at their physician's discretion (d-DEX) before January 2012...
September 2017: European Journal of Hospital Pharmacy. Science and Practice
https://www.readbyqxmd.com/read/29303291/-malign-pleural-mesothelioma-so-far-an-undefeated-tumor
#6
Vítězslav Kolek
Malign pleural mesothelioma is the most frequent primary tumor of the pleura of high aggressiveness. Its most frequent cause is contact with asbestos and, although working with asbestos is already prohibited in developed countries, its incidence is on the increase so far. Diagnostics primarily considers anamnesis, clinical symptoms and immunohistochemical examination of a tumor sample. The basic therapy used over the past 10 years is chemotherapy with cisplatin - pemetrexed combinations. Numerous studies are going on with a different biologically targeted therapy, immunotherapy and other drugs which may improve patients prognosis...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29303126/glycaemic-adverse-drug-reactions-from-anti-neoplastics-used-in-treating-pancreatic-cancer
#7
J Yang, B Jia, J Yan, J He
PURPOSE: Pancreatic carcinoma is the most lethal cancer, with a 5-year survival rate of <5%. Hyperglycemia is one of the severe adverse drug reactions (ADRs) in cancer treatment. The aim was to analyze the blood glucose-related ADR of antineoplastics in treating pancreatic cancer. MATERIALS AND METHODS: Antineoplastic drugs were selected from Martindale-The Complete Drug Reference (36th edition). ADR data were extracted from VigiBase, the WHO Uppsala Monitoring Centre, and the WHO's specialist center for drug safety...
November 2017: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/29300397/correction-kinetic-change-of-serum-carcinoembryonic-antigen-can-early-predict-progression-in-patients-with-metastatic-non-small-cell-lung-cancer-during-maintenance-therapy-with-bevacizumab-plus-pemetrexed
#8
Nasha Zhang, Li Kong, Fang Shi, Wang Jing, Haiyong Wang, Ming Yang, Jinming Yu, Hui Zhu
[This corrects the article DOI: 10.18632/oncotarget.20456.].
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29300270/18f-fluorodeoxyglucose-pet-ct-and-dynamic-contrast-enhanced-mri-as-imaging-biomarkers-in-malignant-pleural-mesothelioma
#9
David O Hall, Clare E Hooper, Julie Searle, Michael Darby, Paul White, John E Harvey, Jeremy P Braybrooke, Nick A Maskell, Vidan Masani, Iain D Lyburn
PURPOSE: The purpose of this study was to compare the use of fluorine-18-fluorodeoxyglucose (F-FDG) PET with computed tomography (CT) and dynamic contrast-enhanced (DCE) MRI to predict prognosis and monitor treatment in malignant pleural mesothelioma. PATIENTS AND METHODS: F-FDG PET/CT and DCE-MRI studies carried out as part of the South West Area Mesothelioma Pemetrexed trial were used. F-FDG PET/CT and DCE-MRI studies were carried out before treatment, and after two cycles of chemotherapy, on patients treated with pemetrexed and cisplatin...
January 3, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29298713/crizotinib-in-patients-with-anaplastic-lymphoma-kinase-positive-advanced-non-small-cell-lung-cancer-versus-chemotherapy-as-a-first-line-treatment
#10
Jianya Zhou, Jing Zheng, Xiaochen Zhang, Jing Zhao, Yanping Zhu, Qian Shen, Yuehong Wang, Ke Sun, Zeying Zhang, Zhijie Pan, Yihong Shen, Jianying Zhou
BACKGROUND: To compare the efficacy of crizotinib, pemetrexed and other chemotherapy regimens as a first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in real world clinical use and to evaluate the +86-571-87,236,876 predictive clinical factors of the efficacy of crizotinib. METHODS: The 73 patients with ALK-positive advanced NSCLC were divided into three groups based on the first-line treatment: first-line crizotinib group (1-CRZ group, n = 32); first-line platinum-based pemetrexed treatment group (1-PP group, n = 28), and first-line chemotherapy platinum-based non-pemetrexed group (N1-PP, n = 12)...
January 3, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29298350/sialic-acid-binding-lectin-from-bullfrog-eggs-inhibits-human-malignant-mesothelioma-cell-growth-in-vitro-and-in-vivo
#11
Takeo Tatsuta, Toshiyuki Satoh, Shigeki Sugawara, Akiyoshi Hara, Masahiro Hosono
Malignant mesothelioma is an aggressive cancer that results from exposure to asbestos. The therapeutic options for this type of cancer are limited; therefore, the development of novel therapeutic agents is urgently required. Sialic acid-binding lectin isolated from Rana catesbeiana oocytes (cSBL) is a novel therapeutic candidate for cancer, which exhibits antitumor activity mediated through RNA degradation. In the present study, we evaluated the effect of cSBL in vitro and in vivo. Xenograft-competent H2452 and MSTO human mesothelioma cell lines were treated with cSBL, and the pathway by which cSBL induces apoptosis was analyzed...
2018: PloS One
https://www.readbyqxmd.com/read/29290253/dynamic-change-of-fatigue-of-pemetrexed-maintenance-treatment-in-the-jmen-trial
#12
Li Zhang, Chandra P Belani, Ping-Hai Zhang, Xin Wang, Lulu Yang, Mauro Orlando, Yi-Long Wu
OBJECTIVES: In the JMEN trial, patients with advanced non-squamous non-small cell lung cancer (NSCLC) without progression after platinum-based first-line therapy derived extended survival, delayed disease progression, and maintained overall quality of life (QoL) from pemetrexed maintenance therapy. However, fatigue was the most common physician-reported non-hematological toxicity in the pemetrexed group. This post hoc analysis investigated dynamic change of fatigue. MATERIALS AND METHODS: Analysis of the overall safety population with squamous and non-squamous NSCLC subgroups included Common Terminology Criteria for Adverse Events to summarize adverse event (AE) rates by cycle and AE investigator-reported severity...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290199/lung-cancer-with-concomitant-double-gene-mutation
#13
Tao Fan, Xiu-Li Liu, Jun Zhou, Ying-Jie Song, Hong Yang, Ya-Nan Wei
A patient presenting with concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation is very rare. We report a non-small cell lung cancer (NSCLC) patient with concomitant EGFR (exon 19-del) mutation and ALK rearrangement. The positron emission tomography-computed tomography (PET-CT) scan revealed a highly metabolic mass lesion in the left lower lobe, measured 5.0 cm in the largest dimension in the S6 segment. Transbronchial lung biopsy (TBLB) showed the pathological diagnosis of invasive adenocarcinoma...
January 2018: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29285372/malignant-mesothelioma-of-the-tunica-vaginalis-testis-a-case-report-and-literature-review
#14
Neng Zhang, Ni Fu, Su Peng, Xu Luo
Malignant mesothelioma of the tunica vaginalis testis is an extremely rare tumor without specific clinical manifestations, mainly including hydrocele formation and a painless mass. We herein present the case of a patient with hydrocele of the left testis, without any other complaints. Tunica vaginalis subinvolution was performed, and postoperative pathological examination revealed a malignant mesothelioma arising from the left tunica vaginalis testis. Whole-body positron emission tomography-computed tomography (PET-CT) and subsequent abdominal and pelvic magnetic resonance imaging (MRI) revealed no evidence of local lymphadenopathy...
December 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29278294/chemotherapy-immunophenoprofiles-in-non-small-cell-lung-cancer-by-personalized-membrane-proteomics
#15
Denise Utami Putri, Po-Hao Feng, Yuu-Hueih Hsu, Kang-Yun Lee, Feng-Wen Jiang, Lu-Wei Kuo, Yu-Ju Chen, Chia-Li Han
OBJECTIVES: No study has addressed how the immune status at the molecular level is affected by first-line pemetrexed and cisplatin (PEM-CIS) combination therapy in patients with non-small-cell lung cancer (NSCLC). Thus, we aimed to identify the immune status from membrane proteome alterations in patients with NSCLC upon PEM-CIS treatment. METHODS: The paired peripheral blood mononuclear cells (PBMCs) were collected from four patients with lung adenocarcinoma before and after the first regimen of PEM-CIS treatment and applied quantitative membrane proteomics analysis...
December 26, 2017: Proteomics. Clinical Applications
https://www.readbyqxmd.com/read/29261000/successful-treatment-using-apatinib-with-or-without-docetaxel-in-heavily-pretreated-advanced-non-squamous-non-small-cell-lung-cancer-a-case-report-and-literature-review
#16
Fengying Wu, Shijia Zhang, Guanghui Gao, Jing Zhao, Shengxiang Ren, Caicun Zhou
Although targeted therapy directed toward driver mutations has produced a significant efficacy benefit for patients with non-small cell lung cancer (NSCLC), many patients do not possess mutations associated with the approved targeted drugs. Angiogenic agents play an important role in the therapeutic strategy for advanced NSCLC. Apatinib is a novel tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. A phase II clinical trial demonstrated the survival benefit of apatinib monotherapy in advanced NSCLC...
December 20, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/29239731/practice-patterns-and-outcomes-for-pemetrexed-plus-platinum-doublet-as-neoadjuvant-chemotherapy-in-adenocarcinomas-of-lung-looking-beyond-the-usual-paradigm
#17
V Noronha, S Zanwar, A Joshi, V M Patil, A Mahajan, A Janu, J P Agarwal, P Bhargava, A Kapoor, K Prabhash
AIMS: Neoadjuvant chemotherapy (NACT) is the standard of care in non-small cell lung cancers (NSCLC) with locally advanced N2 disease. There is a scarcity of data for the pemetrexed-platinum regimen as NACT. Also, apart from N2 disease, the role of NACT in locally advanced NSCLCs for tumour downstaging is unclear. MATERIALS AND METHODS: Non-metastatic adenocarcinomas of lung treated with pemetrexed-platinum-based NACT were analysed. The patients with locoregionally advanced N2 disease and those who were borderline candidates for upfront definitive treatment were planned for NACT after discussion in a multidisciplinary clinic...
November 24, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29239007/pemetrexed-induced-painful-erythematous-nodules-in-both-legs-in-a-patient-with-recurrent-mesothelioma
#18
Mar Llamas-Velasco, Enrique Ovejero-Merino, Javier Fraga, Amaro García-Diez, Ramón Moreno-Balsalobre
No abstract text is available yet for this article.
December 14, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/29238267/augmented-expression-of-cardiac-ankyrin-repeat-protein-is-induced-by-pemetrexed-and-a-possible-marker-for-the-pemetrexed-resistance-in-mesothelioma-cells
#19
Yiyang Qin, Ikuo Sekine, Mengmeng Fan, Yuichi Takiguchi, Yuji Tada, Masato Shingyoji, Michiko Hanazono, Naoto Yamaguchi, Masatoshi Tagawa
Background: Pemetrexed (PEM) is an anti-cancer agent targeting DNA and RNA synthesis, and clinically in use for mesothelioma and non-small cell lung carcinoma. A mechanism of resistance to PEM is associated with elevated activities of several enzymes involved in nucleic acid metabolism. Methods: We established two kinds of PEM-resistant mesothelioma cells which did not show any increase of the relevant enzyme activities. We screened genes enhanced in the PEM-resistant cells with a microarray analysis and confirmed the expression levels with Western blot analysis...
2017: Cancer Cell International
https://www.readbyqxmd.com/read/29229675/evaluation-of-metase-pemetrexed-loaded-peg-plga-nanoparticles-modified-with-anti-cd133-scfv-for-treatment-of-gastric-carcinoma
#20
Lin Xin, Hou-Ting Zhang, Wei-Feng Yang, Yi-Fan Li, Chuan Liu
PEG-PLGA nanoparticles (NPs) modified with anti-CD133 and tumor-targeting single-chain antibody fragment (scFV-NPs) for systemic delivery of methioninase (METase) and pemetrexed for gastric carcinoma were successfully formulated. The structure characterization and biological functions of METase-pemetrexed-loaded scFV-PEG-PLGA NPs (scFV-METase/pemetrexed-NPs) in vitro were investigated. Functional scFV-PEG-PLGA NPs or PEG-PLGA NPs presents low cell cytoxicity in CD133+ SGC7901 cells. scFV-METase/pemetrexed-NPs (scFv-M/P-NP) was more effective in inhibiting tumor growth (including cell growth and migration ability) in CD133 positive expressed gastric cancer cells than METase/pemetrexed-NPs (M/P-NP)...
December 11, 2017: Bioscience Reports
keyword
keyword
8879
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"